While Orthofix’s trauma business is growing slower than the market, it has an enormous opportunity in the U.S.
While Orthofix’s trauma business is growing slower than the market, it has an enormous opportunity in the U.S.
Stay up to date on the orthopedic market’s 4Q performance in 2023 as we update this post with company sales data and industry developments.
Funding announcements came from familiar names and supported well-backed markets like spine and enabling technology.
The device from NovApproach Spine supports the spectrum of anterior approaches with multi-insertion/multi-fixation technology.
Gamma4 is indicated for the treatment of fractures in the intracapsular, trochanteric, subtrochanteric and shaft regions of the femur.
GID BIO completed enrollment for the first of two pivotal Phase III studies to investigate the use of your own stromal vascular fraction cells to treat osteoarthritis of the knee.
SI joint fusion with PainTEQ’s LinQ SI Joint Stabilization System shows promise for treating patients with sacroiliac joint dysfunction.
The patent addresses RemeOs’ magnesium-calcium-zinc alloy composition and includes its use in the manufacturing of orthopedic implants.
As a guest member you get access to more articles and webinars every month.
We’ll send a recovery link to your email.
Return to Homepage